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Summary 
The use of highly active antiretroviral therapy (HAART) in the management of 
human immunodeficiency virus (HIV) restores immune responses against pathogens 
and has greatly decreased mortality. However, in about 25% to 35% of patients 
receiving HAART, the reconstituted immune system leads to a pathological 
inflammatory response, commonly known as immune reconstitution inflammatory 
syndrome (IRIS), which causes substantial short-term morbidity, or even mortality. 
Although we have gleaned some knowledge on IRIS in the past few years, a number 
of unanswered questions remain. In this review, we discuss the definition, diagnostic 
criteria, pathogenesis, risk factors, clinical spectrum including oral manifestations, 
and management of IRIS. 
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Introduction 
Since the introduction of highly active antiretroviral therapy (HAART) in 1995, the 
incidence of opportunistic infections, incidence of acquired immunodeficiency 
syndrome (AIDS), and overall mortality of human immunodeficiency virus (HIV)-
infected individuals have all markedly decreased (Mocroft et al., 2003). It is 
becoming clear, however, that some patients receiving HAART show clinical 
deterioration despite increased CD4+ T-cell counts and decreased plasma HIV viral 
loads (French et al., 2000). This phenomenon has been termed immune restoration 
disease, immune reconstitution syndrome, or paradoxical reactions, because of 
clinical deterioration during the apparent recovery of the immune system. Immune 
reconstitution inflammatory syndrome (IRIS) is another widely used and accepted 
term because of the role of the host inflammatory response (Shelburne et al., 2002). 
The latter term will be used throughout this review.  
 
According to the available literature, about 25% to 35% of HIV-infected patients 
responding to HAART develop IRIS, with the majority of cases occurring within the 
first 60 days of initiating HAART (French et al., 2000; Narita et al., 1998). The 
clinical manifestations of IRIS are diverse and depend on the infectious or 
noninfectious agents involved. However, lack of consensus on the definition of IRIS 
and on standardization in clinical and laboratory diagnosis may result in the labeling 
of any condition after initiation of HAART that is atypical or difficult to classify as 
being IRIS (Reddy and Luzzi, 2005).  
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Whether oral diseases play a role in IRIS is unclear. Recognition of this entity is 
crucial, for successful treatment relies on alleviation of the patient’s symptoms 
without compromising antiretroviral or antimicrobial therapy. To date, only a few 
studies have reported oral lesions in association with IRIS. Hence, the aim of this 
review is to provide an update on IRIS and its clinical manifestations, with special 
attention to oral disease. Citations were searched systematically by two independent 
reviewers using the NCBI PubMed database with the search terms of “immune 
reconstitution inflammatory syndrome”, “immune restoration disease”, or “immune 
reconstitution syndrome”, in combination with “HIV” and subsequently “oral”. 
Further articles in reference lists of key articles were also searched.  
 
Definitions 
Immune reconstitution is defined as a CD4+ count of > 200 cells/mm3 and an increase 
of > or = 100 cells over baseline any time since starting HAART (Arici et al., 2001). 
According to IRIS definitions proposed by different investigators (Table 1), IRIS is 
basically an “unmasking” or paradoxical worsening of a pre-existing infection 
following the initiation of HAART, in the presence of improved immune response 
and a decreasing viral load. Features are consistent with an inflammatory process. The 
lack of consensus on the definition means that diagnosis of IRIS depends heavily on 
exclusion and on case definitions incorporating clinical and laboratory data.  
 
Diagnostic criteria 
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The main challenge in diagnosis is to distinguish IRIS from recurrence or relapse of 
an infection. A few key workers have presented case definitions of IRIS (Tables 2 and 
3) (French et al., 2004; Shelburne et al., 2006). These case definitions include five 
fundamental criteria: (1) confirmed case of HIV, (2) temporal association between 
development of IRIS and initiation of HAART, (3) specific host responses to HAART, 
such as increase in CD4+ cell count and decrease in HIV viral load, (4) clinical 
deterioration characterized by an inflammatory process, and (5) exclusion of other 
causes that may lead to similar clinical presentation. Other causes include drug 
resistance or toxicity, drug malabsorption, patient non-adherence to regimen, super-
infection by other pathogens, delayed recovery of immune function after the initiation 
of HAART, inadequate antimicrobial therapy of the pre-existing infection, and 
development of non-infectious complications (Cheng et al., 2000; French, 1999; 
French et al., 2001; Michelet et al., 1998; Lawn et al., 2005). 
 
Problems still exist with these current diagnostic criteria, however (Lipman and Breen, 
2006). Firstly, they are not clear-cut enough and also do not recognize the time lag 
between commencement of HAART and appearance of IRIS, which has been 
reported to vary from a few weeks to 4 years (Wright et al., 2003). Secondly, in some 
cases, there are no significant differences in the extent of elevation in CD4+ cell count 
and reduction in plasma HIV RNA load among HIV-infected patients who develop 
IRIS and those who do not (French et al., 2000; Jevtovic et al., 2005). Thirdly, most 
studies on IRIS to date are retrospective, and detailed data on the changes that occur 
in host immune responses in cases of IRIS are not clearly documented. Fourthly, there 
are no specific biomarkers for IRIS and a wide range of markers has been used by 
different laboratories to diagnose different pathogens (French et al., 2004).  
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In addition, immune responses in IRIS can sometimes exhibit “compartmentalization”. 
For example, in a patient with IRIS who had multilevel transverse myelitis associated 
with infection with varicella zoster virus, activated lymphocytes were found in the 
cerebrospinal fluid but not in the blood (Clark et al., 2004). Numbers of circulating 
CD4+ and CD8+ cells and their functional competence do not correspond to those in 
infected or inflamed tissues (Lawn et al., 2005). Therefore, measurements from blood 
samples may not accurately reflect the actual concentration of the markers at the 
affected site (Barry et al., 2003; Wilkinson et al., 2005). 
 
Pathogenesis 
In theory, any pathogen that can cause an opportunistic infection (OI) because of 
impaired cellular immune response may imitate the development of IRIS in immune-
reconstituted patients (French, 2009). The mechanism of IRIS is still largely 
speculative and may consist of a combination of three aspects—namely, the degree of 
immune restoration following HAART, underlying antigenic burden, and host genetic 
susceptibility.  
 
Degree of immune restoration  
The potent effect of HAART on suppressing HIV and increasing the level of CD4+ T-
cells is mainly due to a redistribution of cells with a memory (CD45RO) phenotype 
from lymphoid tissue (Carcelain et al., 2001). If viral replication can be maintained at 
a low level, production of naive lymphocytes (CD45RA) will increase owing to the 
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restoration of thymic activity. A rapid change in the CD4+ T-cell count is associated 
with IRIS, with IRIS occurring more frequently among patients who have faster and a 
more marked rise in the CD4+ T-cell count than among others (Michailidis et al., 
2005). Studies on patients presenting with CMV uveitis, Cryptococcus meningitis, 
and tuberculosis show that IRIS is more common when there is extensive disease 
present (Breen et al., 2004; Shelburne et al., 2005a; Karavellas et al., 2001; Jenny-
Avital et al., 2002). These observations may be explained by the exaggerated immune 
response that is triggered by abundant microbial antigens and mediated by a sudden 
increase in antigenic-specific cells (Lipman and Breen, 2006). 
 
Underlying antigenic burden 
In patients who develop an OI while initiating HAART, IRIS may appear as a 
paradoxical relapse of the infection. However, pathogens from samples collected at 
the affected sites may not be cultivable; hence in such cases, the immune response 
appears to be directed toward the antigens of non-viable pathogens. This problem is 
commonly seen in cases of Mycobacterium tuberculosis or cryptococcal infection in 
which IRIS may present months to years after HAART initiation (Breton et al., 2004; 
Burman et al., 2007; Shelburne et al., 2005a; Lortholary et al., 2005a). On the other 
hand, viable pathogens may be isolated from affected sites in patients with subclinical 
infections in whom the infection will be unmasked by immune reconstitution after the 
initiation of HAART.  
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Autoimmunity to innate antigens may play a role in non-infectious cases of IRIS. 
Although there are uncertainties whether autoimmune diseases are related to IRIS, 
evidence so far shows that at least Graves’ disease may be a complication of 
HAART-induced immune reconstitution (Crum et al., 2006; Knysz et al., 2006; Vos 
et al., 2006). Others reports indicate that rheumatoid arthritis and related autoimmune 
diseases can also be causes of IRIS (Bell et al., 2002).  
 
The immunopathology of IRIS is currently believed to be determined mainly by the 
provoking pathogens. In IRIS associated with viruses such as John Cunningham virus 
(JCV is a type of human polyomavirus that is associated with progressive multifocal 
leukoencephalopathy in people with immunodeficiency, such as AIDS), HIV, and 
cytomegalovirus, CD8+ T-cells are found to be the predominate cell type (Gray et al., 
2005; Miller et al., 2004; Mutimer et al., 2002). In contrast, in IRIS associated with 
fungi such as Cryptoccocus and Histoplasma (Lortholary et al., 2005a; Breton et al., 
2006), protozoans such as Leishmania (Blanche et al., 2002), or mycobacteria, 
granulomatous inflammatory reactions can be triggered (Batista et al., 2008; Couppié 
et al., 2004; Philips et al., 2005). Furthermore, there is an increase in circulating T-
cells that produce IFN-γ in patients with IRIS involving M. tuberculosis or 
Cryptococcus (Bourgarit et al., 2006; Tan et al., 2008). Suppuration of lymph nodes 
or other organs in mycobacterial IRIS (Philips et al., 2005; Burman et al., 2007; 
Puthanakit et al., 2005; Meintjes et al., 2008) is thought to be the result of the Th17 
response, which is often mediated by neutrophils (Scriba et al., 2008; Matsuzaki et al., 
2007).  
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Cellular proliferative disease such as Kaposi’s sarcoma may be a consequence of 
production of cytokines that induce cellular proliferation. Tamburini et al. (2007) 
found raised IL-6 and tumor necrosis factor alpha levels in two patients with IRIS 
associated with Kaposi’s sarcoma. Because vascular endothelial growth factor 
decreased dramatically with the onset of Kaposi’s sarcoma, the authors surmised that 
IRIS could be due to reduced production of vascular endothelial growth factor in 
response to the extensive Kaposi’s sarcoma. 
 
Host genetic susceptibility 
Another possible mechanism for IRIS could be the host’s genetic susceptibility to 
effects of the exuberant immune response to antigens during immune reconstitution. 
Human leukocyte antigen and cytokine gene polymorphisms have been reported in 
IRIS secondary to herpesviruses and mycobacterial infections (Price et al., 2002). 
These polymorphisms are responsible for different aspects of the host response and 
may thus explain in part why patients with similar antigenic burden and 
immunological responses to HAART have different IRIS responses (Price et al., 2001; 
Price et al., 2002). 
 
Risk factors 
CD4+ T-cell count 
The evidence on CD4+ T-cell count as a risk factor for IRIS is mixed. Patients with 
relatively high CD4+ T-cell counts, of > 350 cells/μL, when they start HAART rarely 
develop IRIS (Srikantiah et al., 2007). Conversely, patients with low baseline counts 
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seem to have an increased risk of developing IRIS (French et al., 2000; Shelburne et 
al., 2005b; Michailidis et al., 2005). Ratnam et al. (2006) found that patients with 
baseline CD4+ T-cell percentage of < 10% had a three-fold increased risk of IRIS. 
Nevertheless, no significant association between the magnitude of increase in CD4+ 
T-cell count and incidence of IRIS was found in that study or in three others (French 
et al., 2000; Jevtovic et al., 2005; Manabe et al., 2007).  
 
Two other studies showed that IRIS is associated with an increased CD4+ cell 
percentage or ratio of CD4+ to CD8+ T-cells. During the first 30 days of HAART, an 
increase of ≥ 12% in the CD4 percentage had the highest positive predictive value of 
IRIS (Breton et al., 2004), and an increase of > 0.33 in the CD4+ to CD8+ ratio was 
strongly correlated with IRIS (Barry et al., 2002; Breton et al., 2004). Bower et al. 
(2005) found that the only variables to be associated with the development of IRIS 
were a higher CD4+ cell count at the time of diagnosis of Kaposi’s sarcoma and the 
presence of edema linked to Kaposi’s sarcoma.  
 
HIV-1 RNA level 
A rapid initial fall in HIV-1 RNA level within 90 days of starting HAART has been 
proposed as a risk factor for IRIS (Shelburne et al., 2005b). The increased risk may be 
related to the redistribution of memory CD4 lymphocytes as a response to HAART-
induced reduction in HIV-1 RNA levels (Bucy et al., 1999).  
 
Opportunistic infections 
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Evidence that the risk of IRIS is increased by concomitant OIs comes from a report in 
which the incidence of IRIS among a group of patients with disseminated 
cryptococcal fungemia was approximately six times that of patients who had 
cryptococcal infection without cryptococcemia (Lortholary et al., 2005a). Similarly, 
patients with disseminated tuberculosis or extrapulmonary tuberculosis had a higher 
risk of IRIS than did patients with only pulmonary infection (Burman et al., 2007). In 
analyses of timing of HAART administration, the risk of IRIS for patients initiating 
HAART within 2 months of OI diagnosis was 10 times that for other patients 
(Shelburne et al., 2005b; Lawn et al., 2005; Lawn et al., 2007), leading Shelburne et 
al. (2005b) to speculate that OI pretreatment reduces antigenic burden and lessens the 
extent of the immune response triggered by HAART. 
 
Susceptibility to OIs has also been implicated as a possible risk factor. Some patients 
with CMV retinitis were found to be co-infected with other herpesviruses, indicating a 
genetic susceptibility to an immunopathological response against herpesviruses. 
Genetic studies have shown that herpesvirus IRIS I associated with HLA-B44 and 
major histocompatibility complex ancestral haplotypes HLA-A2, -B44, and -DR4 
(Price et al., 2001), as well as allele 1 at a single nucleotide polymorphism in the 
39UTR of the IL12B gene encoding IL-12 p40 (Price et al., 2002). In contrast, alleles 
of other cytokine genes (TNFA-308*2 and IL6-174*G) were associated with 
mycobacterial IRIS but not herpesvirus IRIS (French et al., 2000). 
 
Age and gender 
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Age has not been identified to be a risk factor for the development of IRIS in general 
(French et al., 2004; Shelburne et al., 2005b; Breton et al., 2004). However, younger 
age at initiation of HAART is a strong predictor (Ratnam et al., 2006). Younger age 
groups will have more pronounced immune restoration and hence an increased risk of 
developing IRIS (Florence et al., 2003; Douek et al., 1998).  
 
Bonham et al. (2008) commented that gender is unlikely to be an independent risk 
factor for IRIS. No association between gender and IRIS was found in several 
prospective studies (Burman et al., 2007; Kambugu et al., 2008; Murdoch et al., 
2008). By contrast, some retrospective studies reported a two- to three-fold higher 
risk of IRIS among men (Olalla et al., 2002; Lortholary et al., 2005a; Shelburne et al., 
2005b).  
 
HAART regimen 
Whether the use of protease inhibitors in HAART is a risk factor is unclear. Some 
studies have found no association (Shelburne et al., 2005b; Burman et al., 2007), but 
some have. A regimen containing both a protease inhibitor and a non-nucleoside 
reverse transcriptase inhibitor was associated with the development of IRIS, perhaps 
because of the increased potency of the HAART regimen versus other regimens using 
a single protease inhibitor or non-nucleoside reverse transcriptase inhibitor (Bower et 
al., 2005). Similar results were obtained in another study (Manabe et al., 2007), in 
which multivariate analysis revealed an independent association between boosted 
protease inhibitor use and a decline in viral load.  
  13
 
Antiretroviral regimens before therapy may also influence treatment success or IRIS 
development, as demonstrated in a study in which patients who were antiretroviral 
therapy-naive had a more robust virological and immunological response to therapy 
than patients who were heavily pretreated with antiretroviral drugs (Palella et al., 
2002). 
 
Caveats on identifying risk factors 
Although the mentioned risk factors may be predictive for IRIS in specific study 
populations, the results should not be extrapolated for individuals. Moreover, risk 
factors may be specific to IRIS scenarios with specific pathogens. Therefore, 
generalizations about risk across all IRIS conditions may be inappropriate (Bonham et 
al., 2008). 
  
Clinical spectrum 
There are basically two major clinical scenarios of IRIS. The first one is paradoxical 
IRIS in which a previously treated infection shows a symptomatic relapse. The second 
is unmasked IRIS, which is an accelerated presentation of a new OI that is occult or 
latent when HAART is started. 
 
In principle, every OI can cause IRIS as immune status improves. In most cases, fever 
is a frequent symptom and the majority of clinical manifestations resemble the 
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original disease. Diagnosing and distinguishing IRIS from the primary disease can 
hence be a challenge to clinicians. Other conditions that are reported to be associated 
with IRIS are reactivation of autoimmune diseases such as Graves’ disease (Crum et 
al., 2006; Knysz et al., 2006; Vos et al., 2006) and systemic lupus erythematosus, and 
other non-infectious conditions such as sarcoidosis (Lenner et al., 2001; Li et al., 
2002). 
 
Common pathogens in cases of IRIS are Mycobacterium tuberculosis, Cryptococcus 
neoformans, Mycobacterium avium-complex, cytomegalovirus, hepatitis B, 
Pneumocystis jirovecci, JC virus, and herpesvirus. Commonly reported clinical 
manifestations include tuberculosis, Mycobacterium avium intracellulare infection, 
CMV-associated immune recovery vitritis, immune recovery uveitis, Kaposi’s 
sarcoma, leishmaniasis, cerebral toxoplasmosis, Pneumocystis pneumonia, JC virus-
induced progressive multifocal leukoencephalopathy, and herpes simplex infections 
(Barry et al., 2002; Ratnam et al., 2006; Manabe et al., 2007). Uncommon 
manifestations that have been reported have been summarized by French et al. (2004) 
(Table 4).  
 
Oral manifestations 
In theory, any pathogen that can cause an OI could cause IRIS in immune-
reconstituted patients, and there is no reason to believe the oral cavity would be 
spared. Unfortunately, there are limited studies on the oral manifestations of IRIS. 
The most commonly reported oral diseases associated with IRIS follow. 
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Kaposi’s sarcoma 
Rapid clinical progression of Kaposi’s sarcoma was found in 6.6% of 150 HIV-
infected patients with Kaposi’s sarcoma after commencing HAART (Bower et al., 
2005); three of the 10 patients with IRIS had extensive oral involvement. Feller et al. 
(2008) reported a case of IRIS-associated Kaposi’s sarcoma that was a temporary 
immunoinflammatory reaction brought about by HAART and which was controlled 
effectively by limited systemic cytotoxic chemotherapy. 
 
Oral candidiasis 
A retrospective study in France reviewed the incidence of mucosal candidiasis in 
association with IRIS in 474 patients over a period of 10 years (Nacher et al., 2007). 
There was a significant increase in the incidence of oral and vaginal candidiasis in the 
first 2 months after HAART initiation (13.1/100 and 14.1/100 person-years, 
respectively). However, because only the CD4+ count and a very few other clinical or 
laboratory data were available, the authors could not conclude that the observed 
candidiasis was a definite form of IRIS.  
 
In a retrospective study of 389 patients treated with HAART, Jevtovic et al. (2005) 
demonstrated that in 65 OI episodes that fulfilled the criteria for the clinical OI to be 
defined as IRIS, three patients had C. albicans angular cheilitis. In contrast, Gaitan 
Cepeda et al. (2008) found a relatively high prevalence of oral candidiasis (30%) 
among patients with quantitative evidence of immune reconstitution. Erythematous 
candidiasis was the most common oral lesion detected. Other oral lesions were 
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pseudomembranous candidiasis, angular cheilitis, hairy leukoplakia, and herpes 
labialis. The authors argued that the relatively higher prevalence of oral candidiasis 
could be due to a longer observation period, and a time-analysis confirmed that 
mycotic lesions occurred in later stages of disease.  
 
Oral warts 
King et al. (2002) reported an increased incidence of oral warts (1.6%) in a cohort of 
HIV-infected patients, suggesting that the development of the warts could be partly 
related to immune reconstitution. Although they found no association between 
changes in CD4+ counts and the risk of oral warts, the authors pointed out that IRIS 
has been described previously in patients in the absence of a significant increase in 
CD4+ cell count (Race et al., 1998). Other authors have also reported an increased 
prevalence of oral warts in HIV-infected patients receiving HAART (Patton et al., 
2000; Greenspan et al., 2001; Greenwood et al., 2002). Schmidt-Westhausen et al. 
(2000) found that among 61 of 103 HIV-infected patients who were available for 
examination after 6 months of HAART initiation, the number of oral lesions was 
significantly lower than other patients not receiving HAART. Only five (8.2%) 
patients had oral manifestations, four of whom had condylomata acuminata. The 
authors surmised that this could be due to the less immunocompetent cells produced 
during the initial phase of HAART. However, a close examination of the 
immunological findings showed that the CD4+ count increased while the HIV viral 
load decreased significantly after HAART initiation. Therefore, cases of human 
papillomavirus infection could well be oral manifestations of IRIS.  
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Salivary gland disease 
Ortega et al. (2008a) found that parotid enlargement was the most common oral 
manifestation (57.14%) among HIV-infected patients receiving HAART who showed 
immune reconstitution. An earlier retrospective study of HIV-infected patients 
receiving HAART also showed an increased incidence of salivary gland disease, as 
well as a six-fold increase in the incidence of oral warts (Greenspan et al., 2001). The 
authors commented that the increase in salivary gland disease was not unexpected, 
and considered this change to be part of CD8+ cell diffuse infiltrative lymphocytosis 
syndrome, which has previously been associated with improved prognosis. Whether 
these HIV-related salivary gland diseases represent IRIS-associated diffuse infiltrative 
lymphocytosis syndrome remains to be verified.  
 
Herpes zoster 
A sizeable proportion (7%-12%) of OIs associated with IRIS involved 
mucocutaneous herpes zoster infection (Dunic et al., 2005; French et al., 2000; 
Domingo et al., 2001; Martinez et al., 1998). The incidence of herpes zoster 
infections in patients receiving HAART was three to five times higher than that in 
non-HAART patients (Martinez et al., 1998; Domingo et al., 2001). CD8+ proportion 
at baseline was significantly higher in patients with herpes zoster-associated IRIS than 
in those without IRIS. The rise in CD8+ proportion 1 month after initiation of 
HAART was also significantly higher (Martinez et al., 1998). Most of the patients 
had typical or atypical dermatomal manifestations, although other complications, such 
as acute retinal necrosis, peripheral nerve palsy, myelitis, or encephalitis, have also 
been reported (Martinez et al., 1998; Domingo et al., 2001; Glesby et al., 1995). 
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Other oral symptoms 
Ramírez-Amador et al. (2009) followed a group of HIV-infected individuals receiving 
HAART for up to 12 weeks. In eight patients who fulfilled strict IRIS criteria, two 
developed clinical signs of oral candidosis, two had oral ulcers, one had Kaposi’s 
sarcoma, and three had hairy leukoplakia. These findings illustrate the diversity 
possible in clinical manifestation of IRIS.  
 
In a case described by Ortega et al. (2008b), a 41-year-old HIV-infected white male 
with a history of genital syphilis, condyloma acuminatum, lung tuberculosis, hepatitis 
B and C, and anemia complained of pain and mobility in a premolar. A diagnosis of 
osteonecrosis was made. On the basis of the clinical and laboratory evidence, the 
authors concluded that a relationship between osteonecrosis and IRIS was possible. 
This case again shows the wide clinical spectrum that can be observed in patients with 
IRIS. 
 
Management 
Favorable viral suppression and immune reconstitution have been observed in patients 
with IRIS after 24 months of HAART (Shelburne et al., 2005b). The long-term 
outcome of these patients appears to be comparatively better than that of patients 
without the syndrome. The main role of the clinician is thus to provide reassurance to 
patients. Nevertheless, patients who develop IRIS often require significant 
interventions to minimize short-term morbidity. 
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There are to date no controlled prospective studies from which to formulate treatment 
guidelines for IRIS. The prevention of IRIS depends largely on optimal screening for 
OIs before commencing HAART in order to prevent unmasking and to optimally time 
HAART in patients who are receiving treatment for an OI. It is particularly important 
for clinicians to include IRIS in the differential diagnosis of a patient who presents 
with an inflammatory process after initiation of HAART.  
 
There are different ways to prevent the development of IRIS. Since a low CD4+ T-
cell count is a risk factor for development, some authors have suggested starting 
HAART early before the CD4+ cell count drops to below 100 cells/μL (Jevtovic et al., 
2005). Others suggest delaying HAART for 4 to 8 weeks until the co-existing 
infection resolves (Lortholary et al., 2005b; Blumberg et al., 2003). Given that IRIS 
occurs more frequently if HAART is initiated early when antigens are abundant, or if 
there is more advanced immunosuppression, delaying HAART until the antigen load 
is reduced by antimicrobials will, in theory, reduce the risk of IRIS. Nevertheless, 
patients will be at risk of other AIDS events if HAART is delayed (Dean et al., 2002; 
Dheda et al., 2004). Starting HAART immediately and using prophylaxis against any 
suspected asymptomatic infection could be another option (French, 1999).  
 
When IRIS is diagnosed, treatment options depend on the potential hazards and the 
extent of discomfort for the patient (Goebel, 2005). If IRIS may cause severe 
irreversible damage, such as liver failure or CMV retinitis, HAART may have to be 
stopped until the IRIS infection is checked (Drake et al., 2004). In many cases, IRIS 
is self-limiting and only symptomatic treatment is needed, besides treating the IRIS 
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infection. HAART can be continued if the scenario is not life-threatening. Treatment 
should aim at targeting the infectious agents and monitoring for complications 
secondary to the inflammatory process. Empirical treatment of symptomatic IRIS 
using non-steroidal anti-inflammatory drugs has been reported in a number of case 
reports (Blanche et al., 1998; Lortholary et al., 2005a; Breton et al., 2006). If a 
corticosteroid is used, the risk-benefit should be carefully assessed, particularly for 
patients with mycobacterial disease. Affected patients are capable of generating an 
inflammatory response, so many of them ultimately discontinue secondary 
prophylaxis against the offending pathogen (Bower et al., 2005).  
 
Conclusions 
In the absence of large prospective clinical trials, little is known about IRIS. In the 
next decade, IRIS is likely to become a serious problem, especially when HAART 
becomes more accessible to HIV-infected patients in resource-limited countries. 
Many of these patients will have a high antigenic burden and low CD4+ cell counts 
when starting HAART. Future studies should aim at decreasing the rate of IRIS in 
high-risk groups. The pathophysiology of IRIS is still poorly understood, and 
biomarkers for diagnosis and prediction of IRIS remain to be identified. Pathogen-
specific laboratory studies to validate and refine diagnostic criteria are therefore 
urgently needed. Oral manifestations of IRIS also remain illusive and are another field 
that warrants further clinical research.  
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Table 1. Definitions of immune reconstitution inflammatory syndrome. 
 
Authors Year Definition 
Shelburne et al. 2002 Immune reconstitution inflammatory syndrome is 
defined as a paradoxical deterioration in clinical status 
attributable to the recovery of the immune system during 
HAART. 
Bower et al. 2005 Immune reconstitution inflammatory syndrome may be 
defined as a progressive deterioration in clinical status as 
a result of recovery of the immune system, leading to 
worsening infection despite improvements in surrogate 
markers of HIV. 
 
Goebel 2005 Immune reconstitution inflammatory syndrome describes 
a collection of different inflammatory disorders which 
are associated with paradoxical deterioration of various 
preexisting infectious processes following 
commencement of HAART in HIV-infected patients. 
Lawn et al. 2005 “Immune restoration disease” could be defined as the 
presentation or clinical deterioration of opportunistic 
infections in HIV-infected patients as a direct result of 
the enhancement of immune responses to those 
pathogens during HAART. 
Ratnam et al. 2006 On patients with previous history of infection, recurrent 
disease was defined as an immune reconstitution 
inflammatory syndrome event only if there was 
documented evidence of a significant increased 
frequency, severity, and/or poor treatment response in 
the six months after initiation of HAART. 
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Table 2. Proposed criteria for diagnosis of immune reconstitution inflammatory 
syndrome in HIV patients on antiretroviral therapy* (French et al., 2004). 
 
Major criteria 
 
A. Atypical presentation of “opportunistic infections or tumors” in patients 
responding to antiretroviral therapy (ART). 
• Localized disease, e.g. lymph nodes, liver, spleen 
• Exaggerated inflammatory reaction, e.g.  
o Severe fever, with exclusion of other causes 
o Painful lesions 
• Atypical inflammatory response in affected tissues, e.g. 
o Granulomas, suppuration, necrosis 
o Perivascular lymphocytic inflammatory cell infiltrate 
• Progression of organ dysfunction or enlargement of pre-existing lesions after 
definite clinical improvement with pathogen-specific therapy prior to the 
commencement of ART and exclusion of treatment toxicity and new 
diagnoses, e.g. 
o Development or enlargement of cerebral space occupying lesions after 
treatment for cerebral cryptococcosis or toxoplasmosis 
o Progressive pneumonitis or the development of organizing pneumonia 
after treatment for pulmonary Mycobacterium tuberculosis or 
Pneumocystis carinii pneumonitis 
o New onset or worsening of uveitis/vitritis after the resolution of CMV 
retinitis 
o Fever and cytopenia after treatment for disseminated Mycobacterium 
avium complex 
o Enlargement of Kaposi’s sarcoma lesions and subsequent resolution or 
partial regression without commencement of radiotherapy, systemic 
chemotherapy or intralesional therapy 
 
B. Decrease in plasma HIV RNA level by >1 log10 copies/mL 
 
Minor criteria 
 
• Increased blood CD4+ T-cell count after ART. 
• Increase in an immune response specific to the relevant pathogen, e.g. DTH 
response to mycobacterial antigens 
• Spontaneous resolution of disease without specific antimicrobial therapy or 
tumor chemotherapy with continuation of anti-retroviral therapy 
 
 
* A diagnosis requires both major criteria, or criterion A and two minor criteria. 
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Table 3. Proposed criteria for diagnosis of immune reconstitution inflammatory 
syndrome in HIV patients receiving antiretroviral therapy (Shelburne et al., 2006). 
 
• HIV-positive 
 
• Receiving HAART 
o Decrease in HIV-1 RNA level from baseline 
o Increase in CD4+ cells from baseline (may lag HIV-1 RNA decrease) 
 
• Clinical symptoms consistent with inflammatory process 
 
• Clinical course not consistent with: 
o Expected course of previously diagnosed opportunistic infection 
o Expected course of newly diagnosed opportunistic infection 
o Drug toxicity 
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Table 4. Uncommon clinical manifestations of immune reconstitution inflammatory 
syndrome (French et al., 2004). 
 
 
Pathogen Disease Reference 
   
Parvovirus B19 Encephalitis Nolan et al., 2003 
Skin yeasts Folliculitis Bouscarat et al., 2000 
Leishmania major Uveitis Blanche et al., 2002 
Leishmania infantum Post-kala-azar dermal 
leishmaniasis 
Ridolfo et al., 2000 
Bartonella henselae Granulomatous splenitis Abino et al., 2002 
Microsporidia Keratoconjunctivitis Gajdatsy and Tay-Kearney, 
2001 
Chlamydia trachomatis Reiter’s syndrome Neumann et al., 2003 
 
